CRISPR TherapeuticsCRSP

The company reported a loss of 94 cents per share, which was better than the $1.19 loss analysts expected. While revenue remains small at about 10 million dollars, the focus for a biotech firm at this stage is on how its first approved drug, Casgevy, is performing and how its other research is progressing.

Management noted that Casgevy is gaining traction and recently received approval for children as young as 2 years old. The company also started early-stage trials for two new treatments that work inside the body to treat high blood pressure and a specific lung and liver disorder. This progress is important because it shows the company is moving beyond its first blood-disorder drug into larger markets.

See the full quarter, and how our tracked metrics did

Source: 8-K filing

Key highlights

• Casgevy revenue surge: The company's first approved therapy generated $76 million in the second quarter, a 151% increase over the same period last year as patient access continues to expand globally. This growth is a vital signal for long-term owners that the commercial rollout is successfully gaining steam.
• New patient market expansion: The FDA recently approved Casgevy for children as young as 2 years old, adding approximately 5,500 more people who are now eligible for the treatment. This moves the company closer to its goal of reaching at least 100 total collected patients by the end of 2026.
• Cash reserves strengthened: The company ended the quarter with $2.36 billion in cash and investments, up from $1.98 billion at the end of last year. This increase was driven by a $585.4 million debt sale, giving the business a much longer window to fund its expensive clinical trials.
• Narrowing net losses: The company reported a net loss of $91.2 million, which is significantly lower than the $208.5 million loss from the same quarter last year. This improvement shows that rising revenue from its lead product is starting to offset the high costs of developing new medicines.
• Upcoming clinical milestones: Management expects to provide clinical updates for its heart disease and autoimmune programs in the second half of 2026, including data on CTX310 and the Phase 2 trial of CTX611. These results will be the next major test of whether the company's technology can succeed beyond blood disorders.

Our take: This was a strong quarter that showed the business is successfully making the leap from a research project to a commercial company. The $76 million in Casgevy revenue and the expanded pediatric approval are the critical drivers here. These results strengthen the case that the company can fund its massive pipeline while scaling its first major hit.